-
Michael J. Fox Foundation, Blackfynn Collaborate on Parkinson’s Biomarkers Study
The Michael J. Fox Foundation (MJFF) and Blackfynn are joining forces to make optimal use of an initiative that could uncover Parkinson’s disease biomarkers and bring about new therapies.
Called the Parkinson’s Progression Markers Initiative (PPMI), the MJFF-backed effort is an ongoing observational study of more than 1,300 volunteer participants both with and without Parkinson’s to validate biomarkers and, over time, identify disease risk factors. Participants undergo a battery of tests and assessments. Learn more about this collaboration here.
Did you know about this initiative? What’s your opinion on it?
Sorry, there were no replies found.
Log in to reply.